Compare POWI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWI | VCEL |
|---|---|---|
| Founded | 1988 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1997 | 1996 |
| Metric | POWI | VCEL |
|---|---|---|
| Price | $48.96 | $29.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $61.00 | $58.50 |
| AVG Volume (30 Days) | ★ 881.0K | 610.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.39 | 0.32 |
| Revenue | ★ $443,504,000.00 | $276,259,000.00 |
| Revenue This Year | $8.12 | $19.10 |
| Revenue Next Year | $16.54 | $17.95 |
| P/E Ratio | $128.49 | ★ $96.31 |
| Revenue Growth | 5.86 | ★ 16.45 |
| 52 Week Low | $30.86 | $29.24 |
| 52 Week High | $60.12 | $45.97 |
| Indicator | POWI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 30.58 |
| Support Level | $44.24 | N/A |
| Resistance Level | $51.00 | $38.48 |
| Average True Range (ATR) | 1.84 | 1.52 |
| MACD | 0.28 | -0.18 |
| Stochastic Oscillator | 64.74 | 10.58 |
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.